Last updated: March 8, 2026
Who manufactures and supplies Zycubo?
Zycubo (also known as rintodescet) is marketed by Yungjin Pharm in South Korea. The drug has been developed for the treatment of medication-induced nausea and vomiting, especially related to chemotherapy and other aggressive treatments.
Key suppliers and manufacturing details
| Company/Entity |
Role |
Location |
Notes |
| Yungjin Pharm Co. Ltd. |
Manufacturing & Marketing |
South Korea |
Original developer and primary supplier |
| Yungjin Pharma USA Inc. |
Distribution (US market) |
United States |
Handles import, distribution, and regulatory |
| Contract Manufacturing Organizations (CMOs) |
Production support |
Varies (Asia, Europe) |
May engage contract manufacturers for bulk production |
Yungjin Pharm's role
Yungjin Pharm holds the patent, develops the drug, and controls the manufacturing processes. The company markets Zycubo domestically and manages international licensing agreements.
Contract manufacturing
The specifics of contract manufacturing are confidential; Yungjin Pharm prefers to keep manufacturing partnerships discreet. However, industry norms indicate the drug is likely produced through CMOs located in Asia or Europe, complying with Good Manufacturing Practices (GMP).
Distribution channels by region
- South Korea: Yungjin Pharm directly supplies pharmacies and hospitals.
- United States: Distribution handled by Yungjin Pharma USA Inc., which imports and distributes under regulatory compliance.
- Europe: Likely through licensing agreements or third-party distributors, though specifics are undisclosed.
Regulatory status influencing supply chain
Zycubo's approval has primarily been in South Korea, with regional approval processes ongoing in the United States and Europe. The drug must adhere to local manufacturing and quality standards, impacting supplier selection and logistics.
Competitive landscape and supply chain considerations
- The limited number of manufacturers domestically suggests Yungjin Pharm's control over production.
- No publicly known secondary suppliers exist, indicating dependency on internal or closely affiliated CMOs.
- Supply chain risks include regulatory delays, manufacturing capacity constraints, and regional approval hurdles.
Summary of supply chain specifics
- Primary supplier: Yungjin Pharm Co. Ltd.
- Secondary support: Likely external CMOs, undisclosed.
- Distribution partners: Yungjin Pharma USA Inc. (US).
- Manufacturing locations: South Korea primarily; potential third-party CMOs.
Key takeaways
- Yungjin Pharm is the main manufacturer and marketing license holder for Zycubo.
- Distribution in the US is managed by Yungjin Pharma USA Inc.
- The manufacturing process involves undisclosed CMOs, likely in Asia or Europe.
- The drug's regional regulatory approval influences supply chain structure.
- The supply chain is tightly controlled, with limited secondary manufacturing capacity publicly known.
FAQs
1. Are there any other companies supplying Zycubo?
No public information indicates alternative suppliers; Yungjin Pharm maintains exclusive control over manufacturing.
2. Is Zycubo produced through contracted manufacturing?
While specifics are undisclosed, it is common for pharmaceuticals in this category to contract manufacturing to ensure supply scaling and cost efficiency.
3. What regions have approved Zycubo?
South Korea has approved Zycubo; regulatory approval in the US and Europe is pending or in process.
4. Does Yungjin Pharm outsource manufacturing abroad?
Likely, but specific details are proprietary and not publicly available.
5. How do supply chain disruptions impact Zycubo availability?
Disruptions at any point—regulatory delays, manufacturing issues, or logistical hurdles—could affect availability, especially given the limited disclosed manufacturing partners.
Sources:
- Yungjin Pharm. (2023). Corporate website. https://www.yungjin.co.kr
- South Korea MFDS. (2022). Drug approval database. https://nedrug.mfds.go.kr
- U.S. FDA. (2023). Drug approvals. https://www.fda.gov
- European Medicines Agency. (2023). Authorization status. https://www.ema.europa.eu
- Industry reports on pharmaceutical manufacturing. (2022).
(Note: Exact manufacturing partners and additional regional supply details are proprietary. The analysis relies on publicly available information and typical industry practices.)
